文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

177Lu-FAPI-XT放射配体治疗晚期肉瘤及其他癌症的首个人体剂量递增研究

Safety and efficacy of 177Lu-FAPI-XT radioligand therapy in patients with advanced sarcoma and other cancer entities: first-in-human, dose-escalation study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-10-15

该I期首个人体、开放标签、非随机、剂量递增试验评估了177Lu-FAPI-XT在标准治疗难治的晚期实体瘤患者中的安全性、剂量学和初步疗效,采用加速滴定和3+3设计,起始剂量3.7GBq,每队列递增1.85GBq直至观察到剂量限制性毒性。结果显示耐受性良好,未观察到DLT或≥3级治疗相关不良事件,全身有效剂量为0.039±0.013 Sv/GBq,5/14例(35.7%)达稳定疾病,纤维母细胞性肉瘤亚型中4/8例(50%)达SD,中位无进展生存期4.63个月(95%CI: 1.25, NE)。

要点

  • 177Lu-FAPI-XT耐受良好,未观察到DLT或≥3级治疗相关不良事件
  • 全身有效剂量0.039±0.013 Sv/GBq,全身和肿瘤病灶平均有效半衰期分别为52.13±12.33 h和31.78±15.03 h
  • 5/14例(35.7%)达SD,纤维母细胞性肉瘤亚型中4/8例(50%)达SD,中位PFS 4.63个月(95%CI: 1.25, NE)

核心结论

  • 177Lu-FAPI-XT在晚期实体瘤患者中显示良好的安全性特征,并观察到初步的肿瘤反应迹象。
  • 177Lu-FAPI-XT治疗中完全/部分缓解的缺失提示需要优化策略以提高疗效。

研究设计与样本

  • 该研究为I期、首个人体、开放标签、非随机、剂量递增、研究者发起的试验,采用加速滴定和3+3设计。
  • 研究对象为标准治疗难治的晚期实体瘤患者,接受6周177Lu-FAPI-XT治疗周期,起始剂量3.7GBq,后续队列递增1.85GBq直至观察到DLT。

主要发现

  • 177Lu-FAPI-XT耐受良好,未观察到DLT或≥3级治疗相关不良事件。
  • 全身有效剂量为0.039±0.013 Sv/GBq。
  • 全身和肿瘤病灶的平均有效半衰期分别为52.13±12.33 h和31.78±15.03 h。
  • 根据RECIST,5/14例(35.7%)患者达SD,纤维母细胞性肉瘤亚型中4/8例(50%)达SD。
  • 中位PFS为4.63个月(95%CI: 1.25, NE),2例肉瘤患者PET/CT观察到代谢降低。

关键数值与推荐

  • 起始剂量为3.7GBq,后续队列递增1.85GBq直至观察到DLT。
  • 全身有效剂量为0.039±0.013 Sv/GBq;全身和肿瘤病灶平均有效半衰期分别为52.13±12.33 h和31.78±15.03 h。
  • RECIST评估SD见于5/14例(35.7%)患者,纤维母细胞性肉瘤亚型中4/8例(50%)达SD;中位PFS为4.63个月(95%CI: 1.25, NE)。

临床怎么用

  • 177Lu-FAPI-XT在晚期实体瘤患者中具有良好的安全性,可考虑用于标准治疗难治患者的进一步研究。
  • 纤维母细胞性肉瘤亚型可能从177Lu-FAPI-XT治疗中获得更高疾病稳定获益。
  • 因缺乏完全/部分缓解,需优化治疗策略以提高疗效。

局限性

  • 该研究为I期首个人体剂量递增试验,样本量有限,初步疗效需进一步验证。
  • 完全/部分缓解缺失,提示单药177Lu-FAPI-XT疗效有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This phase I, first-in-human study evaluated the safety, dosimetry, and preliminary efficacy of 177Lu-FAPI-XT, a novel fibroblast activation protein (FAP)-targeted radioligand, in patients with advanced solid tumors refractory to standard therapies. METHODS: This open-label, non-randomized, dose-escalation, investigator-initiated trial had a "accelerated titration" and "3 + 3" design involved a 6-week 177Lu-FAPI-XT treatment cycle in patients with advanced-stage solid tumors at 3.7GBq initially, with subsequent cohorts receiving an incremental 1.85GBq dose increase until dose limiting toxicity (DLT) was observed. RESULTS: 177Lu-FAPI-XT was well tolerated and no DLT or grade ≥ 3 treatment-related adverse events (TRAE) were observed. The whole-body effective dose was 0.039 ± 0.013 Sv/GBq. The mean effective half-lives for the whole-body and tumor lesions were 52.13 ± 12.33 h and 31.78 ± 15.03 h, respectively. According to RECIST stable disease (SD) were observed in 5 (5/14, 35.7%) patients, with the highest benefit observed in fibroblastic sarcoma subtypes with SD presented in 4 (4/8, 50%) patients. The median progression-free survival (PFS) was 4.63 m (95%CI: 1.25, NE). Metabolic reductions on PET/CT were observed in 2 sarcoma cases. (URL: hclinicaltrials.gov . Trial registration: NCT06211647, NCT06197139. Registered 4 January 2024.) CONCLUSION: 177Lu-FAPI-XT demonstrated a favorable safety profile, with preliminary signs of tumor response observed. Complete/partial response deficiency in 177Lu-FAPI-XT therapy necessitate optimized strategies for efficacy improvement.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu H, Guo R, Zhang X, et al. Safety and efficacy of 177Lu-FAPI-XT radioligand therapy in patients with advanced sarcoma and other cancer entities: first-in-human, dose-escalation study. Eur J Nucl Med Mol Imaging. 2025. PMID: 41087606. doi:10.1007/s00259-025-07617-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。